Navigation Links
Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction
Date:7/14/2014

g segment includes contrast media and nuclear imaging agents. Mallinckrodt has approximately 5,500 employees worldwide and a commercial presence in roughly 65 countries. The company's fiscal 2013 revenue totaled $2.2 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

About Questcor Pharmaceuticals, Inc.

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor's specific areas of focus are in the fields of neurology, nephrology, pulmonology and rheumatology, and the company is currently supporting research efforts in a variety of conditions having significant unmet medical need. For more information about Questcor, please visit www.Questcor.com.

Cautionary Statements Related to Forward-Looking Statements

Statements in this document that are not strictly historical, including statements regarding the proposed acquisition, the expected timetable for completing the transaction, future financial and operating results, benefits and synergies of the transaction, future opportunities for the combined businesses and any other statements regarding events or developments that we believe or anticipate will or may occur in the future, may be "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include risks and uncertainties related to, among other things: general economic conditions and conditions affecting the industries in which Mallinckrodt and Que
'/>"/>

SOURCE Mallinckrodt plc
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. FDA Grants Priority Review To New Drug Application For MNK-795 Submitted By Depomed Licensee Mallinckrodt
2. Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan
3. Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application
4. Valeant Pharmaceuticals Completes Sale Of Filler And Toxin Assets To Galderma
5. Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc.
6. Isis Pharmaceuticals to Receive $7.5 Million from Alnylam
7. Cadence Pharmaceuticals Estimates Fourth Quarter and Full Year 2013 Product Revenue and Provides Full Year 2014 Revenue Guidance
8. Jazz Pharmaceuticals Announces Acquisition From Aerial Biopharma Of Rights To A Late Stage Investigational Compound For Excessive Daytime Sleepiness
9. Avanir Pharmaceuticals Pre-announces Preliminary Fiscal 2014 First Quarter Financial Information
10. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aegerion Pharmaceuticals, Inc.
11. Crealta Pharmaceuticals LLC Announces Completion of the Acquisition of Substantially All of the Assets of Savient Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... in two healthcare conferences during the third quarter, the ... Stanley Global Healthcare 2014 Conference.  Alexza,s corporate presentation will ... details on each event are below: , ... 2014 in Boston , MA.  The ...
(Date:7/29/2014)... -- Edwards Lifesciences Corporation (NYSE: EW ), the ... monitoring, today reported net income for the quarter ended June ... and non-GAAP net income of $94.0 million, or $0.88 per ... earlier was $93.3 million, or $0.81 per diluted share, and ... share.  Net sales for the quarter ended ...
(Date:7/29/2014)... -- New high priced hepatitis C drugs will increase ... $2.9 to $5.8 billion next year, according to a ... by the Pharmaceutical Care Management Association (PCMA). Milliman projects ... much as 8.6 percent in 2015 as a result ... The study finds that the majority of ...
Breaking Medicine Technology:Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Edwards Lifesciences Reports Strong Second Quarter Results 2Edwards Lifesciences Reports Strong Second Quarter Results 3Edwards Lifesciences Reports Strong Second Quarter Results 4Edwards Lifesciences Reports Strong Second Quarter Results 5Edwards Lifesciences Reports Strong Second Quarter Results 6Edwards Lifesciences Reports Strong Second Quarter Results 7Edwards Lifesciences Reports Strong Second Quarter Results 8Edwards Lifesciences Reports Strong Second Quarter Results 9Edwards Lifesciences Reports Strong Second Quarter Results 10Edwards Lifesciences Reports Strong Second Quarter Results 11Edwards Lifesciences Reports Strong Second Quarter Results 12Edwards Lifesciences Reports Strong Second Quarter Results 13Edwards Lifesciences Reports Strong Second Quarter Results 14Edwards Lifesciences Reports Strong Second Quarter Results 15Edwards Lifesciences Reports Strong Second Quarter Results 16Edwards Lifesciences Reports Strong Second Quarter Results 17Edwards Lifesciences Reports Strong Second Quarter Results 18Edwards Lifesciences Reports Strong Second Quarter Results 19Edwards Lifesciences Reports Strong Second Quarter Results 20Edwards Lifesciences Reports Strong Second Quarter Results 21Edwards Lifesciences Reports Strong Second Quarter Results 22Edwards Lifesciences Reports Strong Second Quarter Results 23Edwards Lifesciences Reports Strong Second Quarter Results 24Edwards Lifesciences Reports Strong Second Quarter Results 25New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2
(Date:7/30/2014)... Bridgeport, Connecticut (PRWEB) July 30, 2014 ... released a new magnetic sports bracelet for pain relief ... 100 times strength carbonized titanium embedded in a silicone ... titanium. It also has Germanium and is embedded with ... magnetic balance bracelet. , “Pain Free Living has 12 ...
(Date:7/29/2014)... 30, 2014 VisitandCare.com today ... been added to the company’s exclusive network to help ... of joint efforts — as top fertility clinics in ... offer affordable, state-of-the-art, and successful IVF treatments. , The ... a comprehensive study by professionals at VisitandCare.com. The goal ...
(Date:7/29/2014)... MO (PRWEB) July 30, 2014 ... have recently been awarded the Patient-Centered Medical Home ... the National Committee for Quality Assurance. Only one ... NCQA Level I, Level 2, or Level 3 ... participate in Patient-Centered Medical Home report faster access ...
(Date:7/29/2014)... Dignity Sciences Limited, a privately held biopharmaceutical ... I trial with DS107G, an oral formulation of Dihomo ... randomized, placebo-controlled, double-blind, single-ascending and multiple dose Phase I ... of food on DS107G in healthy subjects. , ... following both single and multiple oral doses over 28 ...
(Date:7/29/2014)... July 29, 2014 Daily Gossip indicates ... as all other disturbing symptoms that hemorrhoids commonly causes. ... researcher and natural medicine expert. , The author ... to the elimination of symptoms such as itching, burning, ... Learn more about the H Miracle by visiting the ...
Breaking Medicine News(10 mins):Health News:Superior Magnetics Released New Magnetic Sports Bracelet for Pain 2Health News:Top European Fertility Clinics Join VisitandCare.com 2Health News:Top European Fertility Clinics Join VisitandCare.com 3Health News:Top European Fertility Clinics Join VisitandCare.com 4Health News:Saint Luke’s Medical Group Awarded Patient-Centered Medical Home 2011 Level 3 Recognition 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:H Miracle Review Exposes Natural Method to Cure Hemorrhoids 2
... for growth hormone therapy’s anti-aging powers – says a team ... papers based on growth hormone.// ,'There is certainly ... to an otherwise healthy person will make him or her ... potential for adverse side effects.' - says Dr. Hau Liu, ...
... a member of a large family may not be best ... greatly influenced the development of stomach cancer linked to the ... to be especially vulnerable to the most common type of ... the records of more than 7,000 Japanese-American men who were ...
... have reported an interesting find: statins, or drugs used ... actually have an added benefit; //reduce the chance of ... Australians use pop statins, which are lipid-modifying drugs that ... drug for reducing cholesterol levels. , The drug ...
... ideal world, the answer is no, as breast milk ... ,However, in the same developing countries where the ... is often considered the only safe and nutritious food ... research is needed. ,A new study conducted ...
... true; for fat people and inventors. ,Scientists have always ... Britain are no exception. //Currently, two thirds of the population can ... to put a morbidly obese figure of 2.2 million pounds ... London. ,Bloom’s quest is to create a chewing gum or ...
... chicken eggs that can be used to produce drugs like those ... at Edinburgh, Scotland have claimed to create a flock ... to create life saving drugs. ,These drugs could ... National Health Service incurs, according to them. , For ...
Cached Medicine News:Health News:Is Growth Hormone – a Key to Longevity 2Health News:Link Between Family Size and Stomach Cancer Found 2Health News:Link Between Family Size and Stomach Cancer Found 3Health News:Chew That Fat Away 2Health News:No Pills Just Omelets 2
... The Vasotrax is an ... pressure and heart rate non-invasively, ... fact, significantly more accurate than ... On a full battery charge, ...
... Inhibins are heterodimeric proteins that suppress the ... the pituitary. Inhibin consists of two distinct ... together. Inhibin A consists of the alpha-subunit ... alpha-subunit and betaB-subunit. Only the dimeric forms ...
... II (IGF-II) is a 7.5 kDa peptide which ... postulated to have mitogenic and metabolic actions involved ... mediated by binding to target cell receptors. IGF-II ... IGF receptor, a monomeric protein which also serves ...
... A (PAPP-A) is a large placenta-derived ... high concentrations by placental trophoblast cells, ... circulation in increasing concentrations throughout gestation ... specific to pregnancy since measurable levels ...
Medicine Products: